Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia by Chi, Benjamin H et al.
INFECTIOUS DISEASE
Adherence to first-line antiretroviral therapy
affects non-virologic outcomes among patients
on treatment for more than 12 months
in Lusaka, Zambia
Benjamin H Chi,
1,2* Ronald A Cantrell,
1,2 Isaac Zulu,
3,4 Lloyd B Mulenga,
1 Jens W Levy,
1,2
Bushimbwa C Tambatamba,
5 Stewart Reid,
1,2 Albert Mwango,
6 Alwyn Mwinga,
3 Marc Bulterys,
3
Michael S Saag
2 and Jeffrey SA Stringer
1,2
Accepted 7 January 2009
Background High-level adherence to antiretroviral therapy (ART) is associated
with favourable patient outcomes. In resource-constrained settings,
however, there are few validated measures. We examined the
correlation between clinical outcomes and the medication posses-
sion ratio (MPR), a pharmacy-based measure of adherence.
Methods We analysed data from a large programmatic cohort across 18
primary care centres providing ART in Lusaka, Zambia. Patients
were stratified into three categories based on MPR-calculated
adherence over the first 12 months: optimal (595%), suboptimal
(80–94%) and poor (<80%).
Results Overall, 27115 treatment-naı ¨ve adults initiated and continued ART
for 512 months: 17060 (62.9%) demonstrated optimal adherence,
7682 (28.3%) had suboptimal adherence and 2373 (8.8%) had poor
adherence. When compared with those with optimal adherence,
post-12-month mortality risk was similar among patients with sub-
optimal adherence [adjusted hazard ratio (AHR)¼1.0; 95%CI:
0.9–1.2] but higher in patients with poor adherence (AHR¼1.7;
95% CI: 1.4–2.2). Those <80% MPR also appeared to have an
attenuated CD4 response at 18 months (185 cells/ml vs 217 cells/ml;
P<0.001), 24 months (213 cells/ml vs 246 cells/ml; P<0.001), 30
months (226 cells/ml vs 261 cells/ml; P<0.001) and 36 months (245
cells/ml vs 275 cells/ml; P<0.01) when compared with those above
this threshold.
Conclusions MPR was predictive of clinical outcomes and immunologic response
in this large public sector antiretroviral treatment program.
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Introduction
Adherence to antiretroviral therapy (ART) is ess-
ential for maximal suppression of viral replication and
avoidance of drug resistance.
1–5 As such, good
adherence is believed to be a critical determinant
of long-term survival among HIV-infected individ-
uals.
6–9 Where availability of second-line or salvage
antiretroviral drug regimens is limited, it is espe-
cially important to leverage maximum durability for
first-line regimens.
6
Early studies in Africa reported adherence levels as
high or higher than those observed in developed
countries.
10,11 However, measures used to assess
adherence vary
11 and many have not been validated
in the context of rapid ART scale-up.
12 In this
analysis, we describe the impact of ART adherence
on immunologic response and survival in a large
population of adults initiating ART in Lusaka,
Zambia. We use the medication possession ratio—a
simple metric that has been correlated with virologic
outcomes in developed countries
13–15—to describe the
adherence behaviour of our population.
Methods
In Lusaka, Zambia, a large-scale public sector HIV
care and treatment program was established by the
Zambian Ministry of Health in April 2004. Clinical
care, patient tracking and outcomes monitoring
for the Lusaka program have been described else-
where.
16,17 Briefly, care has been standardized across
all sites according to the Zambian national guidelines
for adult HIV treatment. In the first months of the
program, ART was initiated in individuals with either
a CD4
þ cell count <200cells/ml or WHO stage III/IV.
Since 2005, the Zambian guidelines have been revised,
so that ART eligibility for patients in WHO Stage 3
requires a CD4
þ cell count 4350cells/ml. First-line
drug regimens in Zambia had comprised two nucleo-
side reverse transcriptase inhibitors (lamivudine
with either zidovudine or stavudine) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI;
nevirapine or efavirenz). Since July 2007, however,
the Zambian Ministry of Health has incorporated
combination tenofovir/emtricitabine as a first-line
nucleoside reverse transcriptase inhibitor backbone
for individuals newly initiating therapy; those con-
tinuing therapy remain on their previous regimen
except in cases of toxicity or treatment failure.
18
Antiretroviral drugs provided are free of charge and
dispensed by pharmacy technicians or nurses within
the ART clinic itself. Patients are encouraged to enlist
a ‘buddy’ for adherence support, usually a friend or
family member. These individuals are authorized to
collect a limited number of drug refills when the
patient is unable to attend a pharmacy appointment.
Medical information, including the number of pills
dispensed and the date of next visit, is entered into an
electronic patient tracking system.
19 Patients on ART
who are 410 days late for a scheduled appointment
are followed up by community health workers at their
homes.
20
We calculated adherence based on a variation of
the commonly-reported medication possession ratio
(MPR).
21,22 We divided the number of days late
for pharmacy refills by total days on therapy, and
then subtracted that percentage from 100%. The
resulting figure represents the percentage of days a
patient is known to have medication on hand and has
been correlated with HIV virologic outcomes in Africa.
23
In the Lusaka public sector, patients are provided
a buffer stock of 3 days with each drug dispensation;
therefore, we began calculating lateness on the fourth
day after a missed pharmacy appointment.
24 Since ART
is provided free charge by the Zambian government, the
‘black market’ for antiretroviral drugs is believed to be
minimal to non-existent.
Patients were categorized as optimally adherent
(595%), suboptimally adherent (80–94%) and poorly
adherent (<80%). Owing to the high rates of early
mortality in our setting and others like it,
16,25 we
excluded patients from this analysis who had been
on therapy for <12 months. We reasoned that poor
patient outcomes associated with adherence would
likely manifest later in the course of treatment, after
viral drug resistance and treatment failure had devel-
oped. Early death also introduces bias into the MPR
measurement, since these patients do not have the
same opportunity to fully demonstrate long-term
adherence behaviours. For these reasons, we con-
sidered only adherence behaviour during the first
12 months and evaluated outcomes after 12 months.
Patients are categorized as ‘active’ if they attended
their last scheduled clinical and/or pharmacy visit
within 30 days of their appointment date. ‘Dead’
patients are so classified in the medical record after
confirmation from family members, friends or com-
munity health workers. ‘Inactive’ patients have for-
mally withdrawn from the HIV treatment program.
‘Late’ patients are 430 days overdue for their last
scheduled clinical and/or pharmacy visit and cannot
ART ADHERENCE AND CLINICAL OUTCOMES 747be located via community health worker contact
tracing. In survival analyses and rate calculations,
inactive patients are censored as of the date they
became inactive, and late patients are censored 30
days after their last scheduled visit.
We analysed programmatic data from treatment-
naı ¨ve adults (415 years) initiating ART across 18
primary care sites in Lusaka, Zambia from April 1,
2004 to September 30, 2007. To be included in the
analysis, individuals had to be active for 12 months of
follow-up, so that the MPR measure for adherence
could be calculated. Those who had died, withdrew
from the program or were lost to follow-up prior to
12 months were excluded. To compare demographic
and clinical characteristics among members of the
study population and those who were excluded,
we analysed categorical variables using Pearson’s
Chi-square test. Non-parametric Wilcoxon rank-sum
tests were used to compare continuous variables.
We calculated mortality rates using individual follow-
up time from 12 months onward. We used logistic
regression to describe the association between
these characteristics and adherence to therapy at
12 months. In this multivariable analysis, we included
all covariates associated with adherence at a
P-value<0.10 level.
Log-rank tests were used to evaluate differences in
survival among adherence categories using Kaplan–
Meier analysis; Cox proportional hazards models
were used to assess the risk of death. The propor-
tional hazards assumption was confirmed via the
Kolmogorov-type supremum test (P¼0.83).
26 All fac-
tors associated in crude analysis with P-value<0.10,
or that have been previously shown to be associated
with mortality in our setting,
16 were included in the
multivariable analysis. However, we excluded any
such covariate if it was believed to be an intermediary
step between the exposure and outcome. (For
example, we include enrollment CD4
þ lymphocyte
count in the multivariable models but not later
measures of CD4
þ). In all adjusted models, contin-
uous covariates were categorized based on the con-
ventions in the medical literature. Finally, we
compared clinical and immunologic outcomes (i.e.
CD4
þ count, weight, haemoglobin) longitudinally
according to MPR categories. Means and correspond-
ing 95% CIs at each time point were calculated; trends
were evaluated at each 6-month interval using
separate Student’s t-tests.
Available patient data through November 1, 2008,
the dataset freeze date, were considered in this report.
All analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC, USA), and were approved by
the institutional review boards of the University of
Zambia (Lusaka, Zambia) and the University of
Alabama at Birmingham (Birmingham, AL, USA),
and by the US Centers for Disease Control and
Prevention (Atlanta, GA, USA).
Results
Cohort description
From April 1, 2004 to September 30, 2007, 37039
ART-naı ¨ve adults (415 years of age) initiated treat-
ment across 18 sites in Lusaka, Zambia. Of these,
27115 (73.2%) remained active in the program at
or after 12 months and were thus included in the
analysis. A total of 9924 (26.8%) were excluded from
the analysis because they had left the program before
reaching the 12 month threshold: 1133 withdrew
from the program, 5114 were late for patient visits
and 3677 had died (crude mortality rate¼105.5/100
person-years, 95%CI: 102.1–108.9). A comparison of
those included and excluded from the analysis is
shown in Table 1.
Of the 27115 included in this analysis, 1419 (5.2%)
withdrew from the program, 3067 (11.3%) were late
for their most recent scheduled visit, and 823 (3.0%)
were known to have died (crude post-12 month
mortality rate¼2.1/100 person-years, 95% CI: 2.0, 2.3)
after the initial 12-month period. The median
observation period was 15.7 [interquartile range
(IQR)¼7.5–26.4] months, from 12 months onward.
Of 27115 patients, 17060 (62.9%) demonstrated
optimal adherence, 7682 (28.3%) had suboptimal
adherence and 2373 (8.8%) had poor adherence over
the first 12 months on therapy (Figure 1). Individuals
with an MPR <80% were more likely to have a higher
median CD4 count at enrollment than those with
optimal adherence. When compared with those with
optimal adherence, individuals in the 80–94 and
<80% MPR were generally younger and were less
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Figure 1 Distribution of adherence to ART over the first 12
months on treatment among adults surviving to at least
12 months in Lusaka, Zambia, between April 1, 2004 and
September 30, 2007. Adherence was measured by the
number of days a patient had antiretroviral drugs available
according to pharmacy refill data
748 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYTable 1 Characteristics of treatment-naı ¨ve adults initiating ART in Lusaka, Zambia, from April 1, 2004 to September 30,
2007 and continuing ART for 412 months
Included in analysis Excluded from analysis
N Value N Value P
Age, median years (IQR) 27115 35 (30–41) 9924 34 (29–40) <0.001
15–25 2718 10.0% 1285 12.9% <0.001
26–35 12159 44.8% 4526 45.6%
36–45 8636 31.8% 2884 29.1%
46–55 2875 10.6% 901 9.1%
556 727 2.7% 328 3.3%
Sex
Female 16889 62.3% 5566 56.1% <0.001
Male 10226 37.7% 4358 43.9%
Adherence supporter
No 5469 20.2% 3289 33.1% <0.001
Yes 21646 79.8% 6635 66.9%
CD4
þ lymphocyte count, median cells/ml (IQR) 26068 132 (69–198) 9409 110 (48–191) <0.001
5200 cells/ml 6358 24.4% 2121 22.5% <0.001
50–199 cells/ml 15274 58.6% 4855 51.6%
<50 cells/ml 4436 17.0% 2433 25.9%
WHO Stage
I or II 8741 32.5% 2330 23.8% <0.001
III 15789 58.6% 6057 61.8%
IV 2398 8.9% 1420 14.5%
Haemoglobin, median g/dl (IQR) 23796 10.9 (9.6–12.3) 8370 10.2 (8.7–11.8) <0.001
58.0g/dl 21995 92.4% 7122 85.1% <0.001
<8.0g/dl 1801 7.6% 1248 14.9%
BMI, median kg/m
2 (IQR) 24250 20.0 (18.1–22.3) 8358 18.9 (16.9–21.2) <0.001
520kg/m
2 12147 50.1% 3078 36.8% <0.001
18–19kg/m
2 6148 25.4% 2015 24.1%
16–17kg/m
2 4258 17.6% 1930 23.1%
<16kg/m
2 1697 7.0% 1335 16.0%
Tuberculosis co-infection at enrollment
No 23488 86.6% 8569 86.3% 0.49
Yes 3627 13.4% 1355 13.7%
Initial ART regimen
d4Tþ3TCþNVP 10699 39.7% 4691 48.0% <0.001
ZDVþ3TCþNVP 12996 48.3% 3501 35.8%
d4Tþ3TCþEFV 1523 5.7% 875 8.9%
ZDVþ3TCþEFV 1026 3.8% 423 4.3%
TDFþFTCþNVP 229 0.9% 98 1.0%
TDFþFTCþEFV 448 1.7% 194 2.0%
Adherence by MPR, median (IQR)
a 27115 97.9 (91.2–100.0) 9924 100.0 (92.6–100.0) <0.00l
95–100% 17060 62.9% 7051 71.0% <0.00l
80–94% 7682 28.3% 1412 14.2%
<80% 2373 8.8% 1461 14.7%
aFor those included in the analysis, adherence by MPR was based on behaviour within the first 12 months from ART initation. For
those excluded because they were not active at 12 months, MPR was based on time from ART initiation to censor date.
ART¼antiretrovinal therapy; D4T¼stavudine; ZDV¼zidovudine; 3TC¼lamivudine; NVP¼nevirapine; EFV¼efavirenz.
ART ADHERENCE AND CLINICAL OUTCOMES 749Table 2 Characteristics by adherence
a category for treatment-naı ¨ve adults initiating ART in Lusaka, Zambia, from April 1,
2004 to September 30, 2007 and continuing ART for 412 months
Optimal (95–100%) Sub-optimal (80–94%) Poor (<80%)
N Value N Value P
b N Value P
b
Age, median years (IQR) 17060 35 (30–41) 7682 34 (29–41) 0.03 2373 33 (28–40) <0.001
15–25 1601 9.4% 782 10.2% 0.12 335 14.1% <0.001
26–35 7620 44.7% 3458 45.0% 1081 45.6%
36–45 5525 32.4% 2441 31.8% 670 28.2%
46–55 1863 10.9% 785 10.2% 227 9.6%
556 451 2.6% 216 2.8% 60 2.5%
Sex
Female 10730 62.9% 4685 61.0% <0.01 1474 62.1% 0.46
Male 6330 37.1% 2997 39.0% 899 37.9%
Adherence supporter
reported at enrollment
14057 82.4% 5943 77.4% <0.001 1646 69.4% <0.001
CD4
þ lymphocyte count,
median cells/ml (IQR)
16469 132 (70–196) 7350 129 (68–198) 0.59 2249 139 (73–207) <0.001
5200 cells/ml 3943 23.9% 1804 24.5% 0.60 611 27.2% <0.01
50–199 cells/ml 9699 58.9% 4293 58.4% 1282 57.0%
<50 cells/ml 2827 17.2% 1253 17.0% 356 15.8%
WHO Stage
I or II 5532 32.6% 2436 32.0% 0.19 773 32.9% 0.81
III 9956 58.7% 4467 58.7% 1366 58.1%
IV 1473 8.7% 713 9.4% 212 9.0%
Haemoglobin, median
g/dl (IQR)
15186 10.9 (9.6–12.3) 6657 10.9 (9.6–12.3) 0.42 1953 11.0 (9.5–12.4) 0.49
58.0g/dl 14060 92.6% 6154 92.4% 0.71 1781 91.2% 0.03
<8.0g/dl 1126 7.4% 503 7.6% 172 8.8%
BMI, median kg/m
2 (IQR) 15356 20.0 (18.1–22.3) 6846 20.0 (18.0–22.2) 0.34 2048 19.9 (18.0–22.3) 0.53
520kg/m
2 7725 50.3% 3418 49.9% 0.42 1004 49.0% 0.75
18–19kg/m
2 3909 25.5% 1703 24.9% 536 26.2%
16–17kg/m
2 2653 17.3% 1241 18.1% 364 17.8%
<16kg/m
2 1069 7.0% 484 7.1% 144 7.0%
Tuberculosis co-infection
at enrollment
2382 14.0% 937 12.2% <0.001 308 13.0% 0.19
Initial ART regimen
d4T þ 3TC þ NVP 6731 39.7% 3042 39.9% 0.07 926 39.7% 0.24
ZDV þ 3TC þ NVP 8222 48.5% 3655 47.9% 1119 47.9%
d4T þ 3TC þ EFV 943 5.6% 440 5.8% 140 6.0%
ZDV þ 3TC þ EFV 628 3.7% 298 3.9% 100 4.3%
TDF þ FTC þ NVP 167 1.0% 49 0.6% 13 0.6%
TDF þ FTC þ EFV 271 1.6% 141 1.8% 36 1.5%
Lost to follow-up or
withdrawn after 12 months
2294 13.4% 1404 18.3% <0.001 788 33.2% <0.001
aDefined at 12 months of therapy as the percentage of time on therapy with ART via pharmacy claims.
bBased on comparisons to the optimal adherence category.
ART¼antiretroviral therapy; D4T¼stavudine; ZDV¼zidovudine; 3TC¼lamivudine; NVP¼nevirapine; EFV¼efavirenz.
750 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYlikely to report adherence support (i.e. adherence
‘buddy’) over the first 3 months following ART
initiation. The proportion of individuals with tuber-
culosis at time of ART initiation was lower among
individuals with suboptimal adherence (12.2 vs
14.0%; P<0.001) when compared with those with
optimal adherence. The proportion of patients who
withdrew from the program or were lost to follow-up
after 12 months increased as adherence declined
categorically (Table 2).
Several medical characteristics appeared protective
against poor adherence. Individuals who were 435
years [odds ratio (OR): 0.8; 95%CI: 0.7–0.9] or
reported presence of an adherence ‘buddy’ (OR: 0.5;
95%CI: 0.5–0.6) were less likely to have MPR <80%.
When compared with those with CD4 count 4200
cells/ml, those with lower baseline CD4 counts were
less likely to be poorly adherent over the first 12
months: 50–199cells/ml (OR: 0.9, 95%CI¼0.8–1.0)
and <50cells/ml (OR: 0.8, 95%CI: 0.7–0.9). These
trends remained consistent in multivariable analysis.
Baseline World Health Organization (WHO) clinical
stage, haemoglobin, body mass index (BMI) and
tuberculosis status were not predictive of poor
adherence (data not shown).
Impact of adherence on patient survival
In Kaplan–Meier analysis, individuals with <80%
adherence had a significantly higher risk of death
when compared with those in other adherence
categories (log rank P¼0.0001). Survival was similar
among the remaining two groups (Figure 2). In
unadjusted proportional hazards regression, the rela-
tive hazard for death was 1.7 (95%CI: 1.4–2.1) among
those with poor adherence, when compared with
those with optimal adherence. These findings
remained virtually unchanged in a multivariable
model controlling for sex, age, adherence support,
baseline CD4
þ lymphocyte count, baseline WHO Stage
and initial regimen dispensed [n¼25836; adjusted
hazard ratio (AHR): 1.7; 95%CI: 1.4–2.2]. Baseline
haemoglobin and BMI were not included in this
initial multivariable model, since early versions of our
patient tracking software did not routinely collect
these data. In a separate model that included these
two parameters (n¼20951), the hazard for mortality
associated with poor adherence did not change
appreciably (Table 3).
Impact of adherence on clinical and
immunologic outcomes
While trends in CD4
þ response, haemoglobin response
and weight gain appeared similar for individuals in the
optimal and suboptimal adherence categories, out-
comes generally appeared worse among those with
poor adherence (Figure 3). When compared with
individuals with 580% adherence, for example,
those with poor adherence appeared to have
an attenuated CD4 response at 18 months (185 vs
217 cells/ml; P<0.001), 24 months (213 vs 246 cells/ml;
P<0.001), 30 months (226 vs 261 cells/ml; P<0.001)
and 36 months (245 vs 275 cells/ml; P<0.01).
Figure 2 Post-12-month mortality by adherence category for ART-naı ¨ve adults initiating ART in Lusaka, Zambia, between
April 1, 2004 and September 30, 2007. Adherence was measured by the number of days a patient had antiretroviral drugs
available according to pharmacy refill data. The numbers shown at the bottom of the graph represent the number of
patients active in each adherence category at 6-monthly intervals. Perfect survival in the first 12 months is a result of our
study design. To be eligible for inclusion in this analysis, patients had to remain alive, active, and on ART until at least 12
months
ART ADHERENCE AND CLINICAL OUTCOMES 751Those with <80% MPR in their first 12 months also
had attenuated increases in weight and haemoglobin
at 18 months (5.0 vs 5.8kg; P<0.001 and 1.7 vs
2.0g/dl; P<0.001), 24 months (5.5 vs 6.0kg; P<0.05
and 1.7 vs 2.0g/dl; P<0.001), 30 months (5.8 vs
6.3kg; P<0.17 and 1.8 vs 2.1g/dl; P<0.01) and 36
months (5.6 vs 6.4kg; P<0.06 and 2.0 vs 2.1g/dl;
P¼0.35).
Discussion
We investigated ART adherence in an extremely busy,
public sector ART program in sub-Saharan Africa.
When optimal adherence was defined as MPR595%,
 60% met this criterion. Less than 10% met criteria
for poor adherence (MPR<80%); however, we
observed poor clinical and immunologic response
among individuals in this group. Although routine
viral load data are not available in our setting, the
80% MPR threshold appears to hold some significance
for crude measures of treatment response such as
mortality and CD4
þ lymphocyte count improvement.
MPR and MPR-like measurements for adherence
(e.g. pharmacy refills, timeliness to clinical appoint-
ments) have been closely associated with virologic
and clinical outcomes among patients on ART.
8,9,11,23
We observed increased mortality after 12 months
among those with adherence <80%: a finding similar
to other studies in the published literature. For
example, Hogg and colleagues found that intermittent
use of ART (defined as drug refills of <75%) was
associated with a nearly 3-fold risk in mortality in
British Columbia.
8 Nachega et al.
9 found that adher-
ence to antiretroviral drug refills of <80% was
associated with a 3-fold increase for death in the
South African private sector. The risk for adverse
outcomes observed in this cohort was of a slightly
lesser magnitude when compared with other pub-
lished series. One reason may have been the eligibility
criteria for inclusion in our analysis. To better under-
stand the impact of adherence on later outcomes,
we included only individuals enrolled in the program
for 412 months. Thus, there is selection bias towards
longer term survivors, regardless of drug adherence
behaviour. This is most evident in the baseline
characteristics of the population, where those in the
lower adherence stratifications had somewhat higher
median CD4
þ lymphocyte counts. The attenuated
effect may be a reflection of the higher baseline
mortality risk in Zambia—regardless of immune
status—compared with Canada or South Africa.
As in other studies,
27 we observed an association
between adherence and CD4
þ lymphocyte response.
Individuals with adherence of <80% had an attenu-
ated response at 18, 24, 30 and 36 months when
compared with those at or above this MPR threshold.
Haemoglobin and weight (usually described through
BMI) are other clinical measures shown to be
independently predictive of mortality among patients
initiating ART.
16,28,29 We noted improved recovery
within both parameters among those with adherence
580%. These results lend support to our findings on
patient survival and MPR.
Table 3 Factors associated with post-12-month mortality
among treatment-naı ¨ve adults initiating ART in Lusaka,
Zambia, from April 1, 2004 to September 30, 2007 and
continuing ART for 412 months
Crude Hazard
ratio (95% CI)
Adjusted Hazard
ratio (95% CI)
Adherence
a
Optimal (95–100%) 1.0 1.0
Suboptimal (80–94%) 1.0 (0.9–1.2) 0.9 (0.8–1.1)
Poor (<80%) 1.7 (1.4–2.1) 1.7 (1.4–2.3)
Age
435 years 1.0 1.0
435 years 1.4 (1.2–1.6) 1.4 (1.2–1.6)
Sex
Female 1.0 1.0
Male 1.4 (1.2–1.6) 1.3 (1.1–1.5)
Adherence supporter
No 1.0 1.0
Yes 0.7 (0.6–0.8) 0.7 (0.6–0.9)
CD4 count
5200 cells/ml 1.0 1.0
50–199 cells/ml 1.3 (1.0–1.5) 1.2 (1.0–1.6)
<50 cells/ml 1.9 (1.5–2.3) 1.5 (1.2–2.0)
WHO Stage
I or II 1.0 1.0
III 1.6 (1.4–1.9) 1.4 (1.1–1.7)
IV 2.5 (2.0–3.2) 2.0 (1.5–2.7)
Haemoglobin
58.0g/dl 1.0 1.0
<8.0g/dl 2.0 (1.6–2.5) 1.6 (1.2–2.0)
BMI
516kg/m
2 1.0 1.0
<16kg/m
2 2.2 (1.8–2.8) 1.8 (1.4–2.2)
Initial ART regimen
b
D4Tþ3TCþNVP 1.0 1.0
ZDVþ3TCþNVP 0.7 (0.6–0.8) 0.7 (0.6–0.9)
D4Tþ3TCþEFV 1.1 (0.8–1.4) 0.9 (0.7–1.3)
ZDVþ3TCþEFV 0.8 (0.5–1.1) 0.8 (0.5–1.3)
aAdherence defined by MPR.
bIn adjusted models, tenofovir-based regimens were not
included due to relatively small number of patients who
received these drugs (n¼636) and deaths documented among
this group (n¼2).
ART¼antiretroviral therapy; D4T¼stavudine; ZDV¼ zidovu-
dine; 3TC¼lamivudine; NVP¼nevirapine; EFV¼efavirenz.
752 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYThe post-12-month mortality rate observed in this
cohort (2.1 deaths/100 patient-years) was slightly
higher than what has been reported among HIV-
uninfected individuals in Africa ( 0.6–0.8 deaths/100
patient-years), and well below that of HIV-infected
individuals without access to treatment ( 11–13
deaths/100 patient-years).
30–32 This finding speaks to
the favourable long-term outcomes among patients on
ART. However, we recognize that selection biases may
contribute to these findings as well. Our analysis
cohort comprised individuals who were likely heal-
thier than the general population initiating ART,
having survived beyond periods of highest mortality
risk (i.e. first 90 days on ART) to at least 12 months.
16
Another potential bias may have been caused by
our ascertainment of patient vital status. Although
systems are in place to follow up those with missed
visits, nearly 10% were late for appointments or
withdrew altogether in the post-12-month period, a
scenario common to other sub-Saharan programs.
33 If
a significant proportion of follow-up losses were
related to death—a distinct possibility given the
local tradition of returning to the rural family home
at times of severe illness—then this would lead to
underestimated mortality.
For individual patient care, we recognize that the
utility of our findings may be limited. We focused
on a survival outcome due to constraints of our
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ART ADHERENCE AND CLINICAL OUTCOMES 753programmatic database, but the ability to predict
virologic suppression may be more relevant for clinical
decision making. Bisson and colleagues, for example,
demonstrated that pharmacy refill-based adherence
measures may perform better than CD4
þ monitoring
to predict virologic failure; overall performance of
adherence, however, still led to significant misclassi-
fication of patient outcomes (i.e. missed virologic
failure, unnecessary regimen change) across several
different thresholds.
34 We observed similar findings
among patients with discordant clinical and immu-
nologic treatment responses in Lusaka, suggesting
that MPR measurements alone may be insufficient
to predict virologic suppression.
24 Instead, it should
either be considered as a triaging tool or as part of
more extensive algorithms in predicting virologic
failure. In addition, while 95% adherence threshold
is commonly referenced, recent studies have shown
that even moderate levels (80–90%) of adherence
can result in viral suppression when combination
regimens are used.
35,36 Establishment of adherence
thresholds that reliably predict virologic treatment
failure and viral drug resistance could greatly assist
individual patient care in resource-constrained
settings.
In contrast, our demonstrated association between
MPR and mortality could provide an important
framework for program monitoring in African sett-
ings. In Lusaka, for example, we currently utilize a
programmatic database
19 to generate facility-level
reports for clinical care quality and performance.
37
An aggregate MPR metric could be generated for a
given facility and serve as a clinic-level performance
indicator. Sites with a high proportion of patients
with poor adherence (e.g. <80%) could be identified
and evaluated for potential interventions incorporat-
ing patient reminders, community education or
adherence support.
23,38–40 This feedback loop between
patient outcomes and service improvement is a critical
link to maintaining a high standard of clinical care,
particularly in settings where HIV services are
expanding rapidly and task shifting is employed to
relieve critical health personnel shortages.
41 Aggregate
data could also assist policy makers and program
managers at the district, provincial and national level,
as they tailor specific interventions to optimize
treatment.
To our knowledge, this is the largest African cohort
in the published literature evaluated for adherence,
owing to the unprecedented resources made available
through the Zambian government, the Global Fund
for AIDS, Tuberculosis and Malaria; and the US
President’s Emergency Plan for AIDS Relief. We
believe the pharmacy data to be complete because of
the free antiretroviral drugs provided by the Zambian
Ministry of Health (thus reducing the probability of
drug collection at non-study sites), and standardized
data capture across all sites. One limitation of this
analysis is our reliance on MPR; in many ways, it is a
crude measure of adherence. Although simple to
calculate, it does not describe the actual ingestion of
medication or the pattern of non-adherence (e.g.
frequency, duration). Patient outcomes in this urban
population may also not be representative of those in
rural areas, where a growing number of programs are
now expanding in Africa. Further work is needed to
understand the role of adherence measurements such
as MPR in such settings. Lastly, we were unable to
fully account for the impact of food supplementation
programs that were slowly rolled out in Lusaka
over the observation period. Recent work demon-
strated a clear impact of food supplementation on
individual-level adherence; however, immunologic
and clinical outcomes were unchanged at 6 and 12
months following ART initiation. Whether food
supplementation might have an impact on survival
is unknown.
42
In summary, we demonstrate that MPR correlates
with patient outcomes in the settings of rapid service
scale-up, task shifting and high disease burden. Our
findings are thus applicable to the many urban public
sector programs in Africa seeking to expand services
in the face of significant resource constraint.
Although 80% MPR appears to be an important
threshold for clinical outcomes and survival, its utility
for individual patient care may be limited. MPR
thresholds that correlate with virologic failure and
viral drug resistance should be delineated, given their
direct relevance to clinical care.
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